SCHEMBL3448207

SCHEMBL3448207

COc1ncc(-c2cnc(Nc3cc(C)cc(C)c3)nc2-n2nc(C(F)(F)F)cc2C)cc1C(=O)NS(=O)(=O)CCCN1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.42
PTGER4 P35408 1/20 0.38
MAPK14 Q16539 3/20 0.36
SRC P12931 1/20 0.36
LCK P06239 3/20 0.36
KDR P35968 1/20 0.36
BRAF P15056 5/20 0.35
RAF1 P04049 3/20 0.35
PIK3CA P42336 2/20 0.35
CSF1R P07333 1/20 0.35
DAPK1 P53355 1/20 0.35
GSK3A P49840 1/20 0.35
TRPV4 Q9HBA0 1/20 0.35
JAK3 P52333 1/20 0.34
BTK Q06187 1/20 0.34
FGFR1 P11362 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3R1 P27986 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450163 0.94 PTGER4 (0.41) SYKPTGER4MAPK14SRCLCK
SCHEMBL3449383 0.90 SYK (0.43) SYKPTGER4MAPK14LCKKDR
SCHEMBL3450297 0.88 SYK (0.37) SYK
SCHEMBL3456932 0.87 SYK (0.38) SYK
SCHEMBL3447949 0.84 SYK (0.42) SYK
SCHEMBL3451603 0.84 PTGER4 (0.41) SYKPTGER4MAPK14SRCLCK
SCHEMBL3450237 0.82 SYK (0.38) SYK
SCHEMBL3447680 0.82 SCN5A (0.36) SYKLCKDAPK1BTK
SCHEMBL3449319 0.81 DAPK1 (0.36) SYKLCKDAPK1BTK
SCHEMBL3448294 0.81 TYRO3 (0.36) SYKMAPK14SRCBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD SYK 804/4885PTGER4 549/4885MAPK14 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.